New drugs and dosage forms

December 2010
American Journal of Health-System Pharmacy;12/1/2010, Vol. 67 Issue 23, p1974
Academic Journal
The article offers information related to several drugs and its administration including Bromfenac ophthalmic solution, Lurasidone hydrochloride tablets, and Risedronate Sodium delayed-release tablets.


Related Articles

  • New drugs and dosage forms.  // American Journal of Health-System Pharmacy;11/1/2010, Vol. 67 Issue 21, p1788 

    The article offers information on the use of new drugs for specific treatments including dexamethasone intravitreal implant for noninfectious ocular inflammation, combination of drospirenone, ethinyl estradiol, and levomefolate calcium tablets and levomefolate calcium tablets for pre-menstrual...

  • Review: non-steroidal anti-inflammatory drugs may reduce schizophrenia symptom severity in the short term when added to antipsychotics. Xiaoduo Fan; Xueqin Song // Evidence Based Mental Health;Feb2013, Vol. 16 Issue 1, p10 

    The authors comment on the efficacy of non-steroidal anti-inflammatory drugs (NSAIDs) at reducing schizophrenia symptom severity when given in addition to antipsychotic medication. The study revealed that use of an NSAID to augment antipsychotic drugs has a moderate beneficial effect on...

  • Nepafenac Ophthalmic.  // AHFS Consumer Medication Information;Oct2017, p1 

    Ophthalmic nepafenac is used to treat eye pain, redness, and swelling in patients who are recovering from cataract surgery (procedure to treat clouding of the lens in the eye). Nepafenac is in a class of medications called nonsteroidal anti-inflammatory drugs (NSAIDs). It works by stopping the...

  • Bromfenac Ophthalmic Solution 0.07 %: A Review of Its Use After Cataract Surgery. Hoy, Sheridan // Clinical Drug Investigation;Aug2015, Vol. 35 Issue 8, p525 

    The nonsteroidal anti-inflammatory drug bromfenac has recently been reformulated with a lower pH to facilitate a reduction in the concentration of bromfenac (to 0.07 %) while ensuring an ocular bioavailability similar to that of the 0.09 % formulation. Bromfenac ophthalmic solution 0.07 %...

  • Modified-release prednisone improves rheumatoid arthritis symptoms. Siddall, Rhonda // British Journal of Hospital Medicine (17508460);Sep2010, Vol. 71 Issue 9, p491 

    The article reports on a clinical study presented at European League Against Rheumatism (EULAR) which indicated that a modified-release formulation of low-dose prednisone improves rheumatoid arthritis symptoms and morning stiffness.

  • Modified-release prednisone improves rheumatoid arthritis symptoms. Siddall, Rhonda // British Journal of Hospital Medicine (17508460);Aug2010, Vol. 71 Issue 8, p431 

    The article offers information on the therapeutic use of modified-release prednisone in rheumatoid arthritis.

  • Halobetasol propionate 0.05 % cream: a guide to its use in the treatment of plaque psoriasis. Lyseng-Williamson, Katherine // Drugs & Therapy Perspectives;Apr2013, Vol. 29 Issue 4, p102 

    Topical halobetasol propionate 0.05 % (Halobex, Halovate, Ultravate and others), a super-potent topical corticosteroid, is effective and well-tolerated in the short-term treatment of plaque psoriasis. Topical combinations of halobetasol propionate 0.05 % and other agents have also shown...

  • Rifampicin-isoniazid induced fatal fulminant hepatitis during treatment of latent tuberculosis: A case report and literature review. Khan, Fahmi Yousef; Rasoul, Fatima // Indian Journal of Critical Care Medicine;Apr-Jun2010, Vol. 14 Issue 2, p97 

    A 42-year-old Indian man received 450 mg rifampicin (RIF) and 150 mg isoniazid (INH) daily after being diagnosed of a latent tuberculosis infection. Baseline serum aminotransferase and total bilirubin levels were within normal limits. On day 31 of treatment, the patient experienced epigastric...

  • Careful analysis essential in selecting ophthalmic NSAIDs. Devgan, Uday // Ocular Surgery News;2/25/2008, Vol. 26 Issue 4, p23 

    The article focuses on the selection of the appropriate nonsteroidal anti-inflammatory drug (NSAID) for perioperative use for patients undergoing cataract or lens surgery. According to the author, bromfenac is the only ophthalmic NSAID approved for twice-daily administration while the others...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics